Because symptomatic treatment is typically the only treatment option available for HLD15 and other HLDs [11], it is necessary to investigate how HLD15 causes hypomyelinating leukodystrophy and its other symptoms at the molecular and cellular levels as knowledge of these pathological mechanisms may enable us to develop therapeutic treatment options and identify therapeutic target molecules. This evidence concerns the gene EPRS1 and leukodystrophy.